Compare · MDLN vs SOLV
MDLN vs SOLV
Side-by-side comparison of Medline Inc. (MDLN) and Solventum Corporation (SOLV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SOLV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $42.58B, about 2.9x SOLV ($14.92B).
- Both names hit the wire about 4 times in the past 4 weeks.
- MDLN has more recent analyst coverage (25 ratings vs 21 for SOLV).
- Company
- Medline Inc.
- Solventum Corporation
- Price
- -
- -
- Market cap
- $42.58B
- $14.92B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2024
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 21
Latest MDLN
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
Latest SOLV
- Chief Executive Officer Hanson Bryan C converted options into 67,261 shares and covered exercise/tax liability with 26,468 shares, increasing direct ownership by 28% to 185,515 units (SEC Form 4)
- Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
- SEC Form 4 filed by SVP, Controller & CAO Zieselman Neil Craig
- SEC Form 3 filed by new insider Zieselman Neil Craig
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- SEC Form 10-Q filed by Solventum Corporation
- Solventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solventum Reports Second Quarter 2026 Financial Results
- Solventum Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Solventum Announces Intent to Separate its Health Information Systems Business